Can muscle strength predict lung cancer survival?
NCT ID NCT06730685
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways to better support patients and create more personalized treatment plans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors design more personalized treatment plans and supportive care strategies for lung cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve outcomes for participants, and results may not apply to all lung cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who have been diagnosed and treated at Zealand University Hospital, Naestved Hospital
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years of age * Diagnosed with lung cancer (all types and stages) and scheduled for oncological treatment * More than 3 months expected survival Exclusion Criteria: * Competing cancer * Pregnancy * Severe physical or cognitive disabilities preventing physical testing and informend consent * Not able to read and understand Danish
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zealand University Hospital
Næstved, Region Sjælland, 4700, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wearables guide home prehab for older lung cancer patients
- Can immunotherapy outperform chemotherapy for lung cancer?
- Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
- Wearable tech and digital rehab may shorten recovery between lung cancer surgeries
- A deep dive into tumor markers could personalize lung cancer care
- Can armored CAR t cells take down Hard-to-Treat neuroendocrine cancers?